Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal epithelial cell tight junction complexes are multi-protein structures that form a selective barrier between adjacent epithelial cells, regulating the paracellular movement of ions and solutes while excluding pathogens (Groschwitz & Hogan, 2009). These complexes consist of transmembrane proteins such as claudins, occludin, and junctional adhesion molecules (JAMs), which are linked to the actin cytoskeleton via peripheral membrane proteins like zonula occludens (ZO-1, ZO-2, and ZO-3). In healthy individuals, these junctions maintain intestinal homeostasis, but their dysfunction is a central feature of "leaky gut" associated with Crohn's disease, ulcerative colitis, and celiac disease (Fasano, 2011). Therapeutic interventions target these complexes to either restore barrier integrity or temporarily increase permeability for enhanced drug delivery. For example, larazotide acetate is a zonulin antagonist designed to prevent tight junction disassembly in celiac disease, while lubiprostone has been shown to stabilize these complexes via ClC-2 chloride channel activation (Cuppoletti et al., 2012). Monitoring these complexes often involves measuring biomarkers like serum zonulin or performing functional permeability assays such as the lactulose/mannitol test. The regulation of these junctions is also influenced by dietary factors and the gut microbiota, making them a focal point for both pharmaceutical and nutraceutical research (Suzuki, 2013). Understanding the molecular architecture of these complexes is essential for developing treatments that can restore intestinal homeostasis and prevent systemic inflammation.
Regulation of paracellular permeability by modulating the assembly and expression of transmembrane proteins such as claudins and occludin, or by inhibiting the zonulin signaling pathway that triggers junction disassembly (Fasano, 2011; Suzuki, 2013).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal epithelial cell tight junction complexes (TJ).